Checchi Capital Advisers LLC Purchases 440 Shares of GSK plc (NYSE:GSK)

Checchi Capital Advisers LLC lifted its position in shares of GSK plc (NYSE:GSK) by 3.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,885 shares of the pharmaceutical company’s stock after purchasing an additional 440 shares during the quarter. Checchi Capital Advisers LLC’s holdings in GSK were worth $402,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Sunbelt Securities Inc. lifted its holdings in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after acquiring an additional 302 shares in the last quarter. Indiana Trust & Investment Management Co raised its position in shares of GSK by 200.0% during the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust bought a new position in shares of GSK during the 4th quarter valued at about $26,000. ST Germain D J Co. Inc. grew its position in shares of GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares during the period. Finally, Sierra Ocean LLC acquired a new position in shares of GSK in the 4th quarter valued at approximately $32,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Ratings Changes

GSK has been the topic of several research analyst reports. Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and lowered their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Finally, Morgan Stanley initiated coverage on GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat, GSK presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Down 0.2 %

Shares of GSK stock opened at $37.33 on Friday. The firm’s fifty day moving average price is $34.91 and its two-hundred day moving average price is $37.30. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92. The firm has a market capitalization of $77.36 billion, a P/E ratio of 23.47, a PEG ratio of 1.12 and a beta of 0.64.

GSK (NYSE:GSK) last released its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. On average, equities analysts predict that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be issued a $0.3932 dividend. This represents a $1.57 annualized dividend and a dividend yield of 4.21%. The ex-dividend date is Friday, February 21st. This is an increase from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio is presently 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.